Overview

Breo Ellipta is a prescription drug approved by the Food and Drug Administration (FDA) in 2013 for daily maintenance treatment in cases of chronic obstructive pulmonary disease (COPD). Breo Ellipta helps prevent bronchospasms. Breo Ellipta may also be used to help reduce COPD exacerbations.

Breo Ellipta is a combination drug containing both Fluticasone and Vilanterol. Fluticasone is a glucocorticoid steroid, a drug that suppresses the immune system. Fluticasone is believed to work by reducing inflammation in the lungs, lowering the risk of bronchospasm. Vilanterol is a long-acting bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making i... read more

Breo Ellipta (Fluticasone/Vilanterol) Questions

MyCOPDTeam is a free social network that makes it easy to find others like you and gain insights from others living with COPD.
Sign up Log in